Powerful Purpose

Healthcare Providers

We work with healthcare providers to support their patients in research studies and clinical trials. The University of Southern Alzheimer’s Disease Research Center has a wide variety of opportunities for volunteers to participate in important research studies designed to discover ways to prevent, treat, and ultimately eradicate Alzheimer’s disease and other dementias.

Please call us at (323) 442-7600

ALLO Clinical Trial

USC is conducting an early phase clinical trial to evaluate the safety and effect of an experimental drug, allopregnanolone (Allo) on memory. The trial consists of a 16 week study to compare Allo to placebo. The study appointments will consist of cognitive assessment, brain scans, and study related care.

To qualify one must be: Age 55 or older
Diagnosed with: Mild Cognitive Impairment (MCI) or Alzheimer’s Disease (AD)

Qualified participants may receive:
Physical and neurological exams, cognitive testing & MRI scans (brain imaging) Transportation to appointments

Contact: USC Alzheimer Disease Research Center (ADRC)
Attn: Gerson Hernandez (gersonhe@usc.edu)
323-865-ALLO (2556)
323-442-7600

For further information: http://clinicaltrials.gov/show/NCT02221622

A4 Study for healthy older adults

The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (the “A4 study” for short) is a clinical study for older individuals (65 to 85 years of age) who may be at risk for memory loss due to Alzheimer’s disease (AD).

The A4 study is investigating a new drug intervention that may reduce the impact of a protein known as “amyloid” or “beta amyloid” forming plaques in the brain. Scientists believe that accumulation of amyloid in the brain may play a key role in the eventual development of AD-related memory loss. The A4 anti-amyloid investigational drug targets amyloid build-up in the brain with the aim of slowing memory loss associated with the development of AD.

Am I eligible?
• The A4 study will enroll 1,000 people between the ages of 65 through 85 with normal thinking and memory function but with evidence of amyloid plaque buildup in the brain.
• Physicians and researchers will use PET amyloid imaging scans to determine whether a potential participant has evidence of elevated amyloid buildup
• Individuals with elevated amyloid on the PET scan will be eligible to become participants in the A4 clinical study.

For further information, please contact us:
USC Alzheimer Disease Research Center
Nadine Diaz, MSW (ndiaz@usc.edu)
(323) 442 – 7600

The ENGAGE Study of Aducanumab for Early Alzheimer’s Disease

This clinical trial evaluates the safety and efficacy of an investigational medication called aducanumab, to determine whether it slows symptoms of Alzheimer’s disease such as memory problems or thinking clearly. Aducanumab is a new type of medication, an antibody that binds to and removes the amyloid fibers that make up the amyloid plaques in the brain that are a part of Alzheimer’s disease. It is believed that removing these fibers will reduce the plaques and improve or slow down the symptoms.

Eligible participants will be between 50 and 85 years old, and experience problems with memory or thinking. Some may have been diagnosed with mild cognitive impairment or mild Alzheimer’s disease previously. Participating in the study will involve visits to USC usually once per month to receive intravenous infusions of aducanumab or an inactive infusion over the course of two years. The trial is being conducted at approximately 150 sites in more than 20 countries in North America, Europe and Asia Pacific.

For more information, please contact us:
USC Alzheimer’s Disease Research Ctr.
Nadine Diaz, MSW at ndiaz@usc.edu
(323) 442-7600

The CREAD Study of Crenezumab for Early Alzheimer’s Disease

The CREAD study is designed to see if an investigational medication called crenezumab can slow the progression of early to mild Alzheimer’s disease. Crenezumab is an antibody that binds to the amyloid in the brain. The amyloid is thought to contribute to the Alzheimer’s disease and the goal of this study is to reduce the amount of amyloid in the brain.

Participants may be able to take part if you are between 50-85 years old, have mild Alzheimer’s disease, or memory problems that may be the early symptoms of Alzheimer’s. Half of the participants enrolled in the study will receive the investigational study medication. The other half will receive a placebo, which contains no active ingredient. The study medications will be given as a 60-minute intravenous infusion every 4 weeks over a period of 2 years. After this time, there may an open-label extension study where all participants receive the investigational study medication.

For more information, please contact us:
USC Alzheimer’s Disease Research Ctr.
Nadine Diaz, MSW at ndiaz@usc.edu
(323) 442-7600

Completed Treatment Studies